Keywords
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

23938 Search results.

Eligibility Lymphoma NCT01403636

- 7/14/20 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01403636

Eligibility Lymphoma NCT01394640

- 7/14/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01394640

Eligibility Lymphoma NCT01321008

- 7/14/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stage I/II Nasal NK Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01321008

Eligibility Lymphoma NCT01244009

- 7/14/20 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: Criteria
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002); ODM derived from: https://clinicaltrials.gov/show/NCT01244009

Eligibility Lymphoma NCT01022021

- 7/13/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine; ODM derived from: https://clinicaltrials.gov/show/NCT01022021

Eligibility Lymphoma NCT00770224

- 7/13/20 - 1 form, 1 itemgroup, 21 items, 1 language
Itemgroup: Criteria
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00770224

COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) - Risk Assessment

- 7/12/20 - 1 form, 8 itemgroups, 14 items, 1 language
Itemgroups: Suicidal behavior; Self-Injurious Behavior, Feeling suicidal (finding), Feeling suicidal (finding), Event, Activation action, Feeling suicidal, Patient Treatment History, Feeling suicidal, Risk factors, Other, Clinical Status, Feeling suicidal, Protective Factors, Suicidal Behavior, Description; Self-Injurious Behavior, Description, Aggressive Behavior, Discription
Posner, Brent, Lucas, Gould, Stanley, Brown, Fisher, Zelazny, Burke, Oquendo, & Mann © 2008 The Research Foundation for Mental Hygiene, Inc. The Columbia Lighthouse Project provides the Columbia Protocol, also known as the Columbia-Suicide Severity Rating Scale (C-SSRS), for use in a multitude of community and healthcare settings. These are places where individuals and teams have the access and opportunity to systematically assess risk and save lives. Examples include: First response agencies, such as police and fire departments Healthcare facilities Military installations Colleges and schools Correctional facilities

Eligibility Lymphocytic Leukemia, Chronic NCT01414205

- 7/12/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE); ODM derived from: https://clinicaltrials.gov/show/NCT01414205

Eligibility Lymphocytic Leukemia, Chronic NCT01271010

- 7/12/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status; ODM derived from: https://clinicaltrials.gov/show/NCT01271010

Eligibility Lymphocytic Leukemia, Chronic NCT01263704

- 7/12/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01263704

Eligibility Lymphocytic Leukemia, Chronic NCT01056510

- 7/11/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe); ODM derived from: https://clinicaltrials.gov/show/NCT01056510

Eligibility Lymphoblastic Leukemia, Acute T-cell NCT01363817

- 7/11/20 - 1 form, 3 itemgroups, 10 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01363817